Drug Profile
Research programme: anticancer therapeutics - ORIC Pharmaceuticals
Alternative Names: OP 3713Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator ORIC Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action 5-nucleotidase inhibitors; Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Triple negative breast cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for research development in Cancer in USA (PO)
- 28 May 2022 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in USA (PO)
- 22 Jun 2020 Pharmacodynamics data from a preclinical study of CD73 inhibitor presented at the111th Annual Meeting of the American Association for Cancer Research - II (AACR-II-2020)